The role of IL-17 in psoriasis. (February 2015)

• Record Type: Journal Article
• Authors: Malakouti, Mona; Brown, Gabrielle Elena; Wang, Eva; Koo, John; Levin, Ethan C.
• Is Part Of: Journal of dermatological treatment. Volume 26:Number 1(2015:Feb.)
• Page Start: 41
• Page End: 44
• Publication Date: 2015-02
• Subjects: Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.3109/09546634.2013.879093
• Languages: English
• ISSNs: 0954-6634

Abstract

<abstract> <title>Abstract</title> <p> <italic>Background</italic>: Psoriasis is a chronic skin condition traditionally believed to involve the Th1 pathway. Recently, the IL-23/Th17/IL-17 pathway has been highlighted in the pathogenesis of psoriasis and other autoimmune inflammatory conditions. From a clinician's perspective, we sought to review the basic science data relevant to IL-17's role in psoriasis pathogenesis.</p> <p> <italic>Methods</italic>: We performed a Pubmed and Web of Knowledge search for English articles starting from 1990 that discussed the Th17 pathway. Search terms such as "IL-17" and "psoriasis" were utilized.</p> <p> <italic>Results</italic>: The IL-17 pathway is regulated by IL-23, a cytokine that is vital for the expansion and maintenance of the Th17 cell population. Th17 derived cytokines (IL-17A, IL-17F, IL-17A/F and IL-22) were elevated in both psoriasis-like murine models and human psoriatic lesional biopsies. Ixekizumab (anti-IL-17A) treatment of psoriasis was found to normalize levels of IL-17 downstream gene products.</p> <p> <italic>Conclusion</italic>: Both preclinical and clinical studies support the central role of IL-17 in the pathogenesis of psoriasis.</p> </abstract>